To unlock the power of RNA and enable the advancement of transformative medicine

As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules.

On this mission, we are driven by scientific rigor, uninhibited curiosity, the spirit of collaboration, integrity, and most importantly, the duty to do good for the world.

Company Leadership